Search
FDA Grants Rare Pediatric Designation to Treatment With NEO100 in Brain Cancer
- OPACC
- 1 day ago
- 1 min read
The FDA has granted Rare Pediatric Disease Designation for NEO100 in the treatment of pediatric-type diffuse high-grade gliomas, a type of brain cancer.
Recent Posts
See AllUntreated growth hormone deficiency was associated with neurocognitive impairment and reduced physical functioning among adult survivors...
A Phase I clinical trial demonstrated that a targeted approach to treating a deadly brain tumor in children called diffuse intrinsic...
A pan-Canadian team has developed a new way to quickly find personalized treatments for young cancer patients, by growing their tumors in...
Comments